Stockreport

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

Immunome, Inc.  (IMNM) 
PDF New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026IM-1021 Phase 1 ongoing with initial data expected in 2026Three IND s [Read more]